3 ASX Growth Companies With Insider Ownership Up To 38%
In This Article:
In the last week, the Australian market has been flat, but it has shown impressive growth over the past year with a 16% increase and an annual earnings growth forecast of 13%. In this context, identifying growth companies with significant insider ownership can be particularly appealing as it often indicates confidence from those closest to the business in its future prospects.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name | Insider Ownership | Earnings Growth |
| SKS Technologies Group (ASX:SKS) | 32.4% | 24.8% |
| Medallion Metals (ASX:MM8) | 13.8% | 72.7% |
| Catalyst Metals (ASX:CYL) | 14.8% | 33.1% |
| Acrux (ASX:ACR) | 19.5% | 91.6% |
| AVA Risk Group (ASX:AVA) | 15.7% | 77.3% |
| Pointerra (ASX:3DP) | 20.8% | 126.4% |
| Newfield Resources (ASX:NWF) | 31.5% | 72.1% |
| Plenti Group (ASX:PLT) | 12.8% | 120.1% |
| Brightstar Resources (ASX:BTR) | 16.2% | 84.6% |
| Findi (ASX:FND) | 34.8% | 112.9% |
Let's dive into some prime choices out of the screener.
Liontown Resources
Simply Wall St Growth Rating: ★★★★★☆
Overview: Liontown Resources Limited focuses on the exploration, evaluation, and development of mineral properties in Australia with a market cap of A$1.52 billion.
Operations: Liontown Resources Limited does not currently report any revenue segments.
Insider Ownership: 14.7%
Liontown Resources is positioned for significant growth, with revenue expected to increase 40.1% annually, outpacing the Australian market. Despite currently generating less than US$1 million in revenue, the company is forecasted to become profitable within three years. Insiders have shown confidence by buying more shares than selling recently. However, concerns exist regarding its financial stability as auditors expressed doubts about its ability to continue as a going concern after reporting a net loss of A$64.92 million for FY2024.
-
Click to explore a detailed breakdown of our findings in Liontown Resources' earnings growth report.
Mesoblast
Simply Wall St Growth Rating: ★★★★★☆
Overview: Mesoblast Limited is involved in developing regenerative medicine products across Australia, the United States, Singapore, and Switzerland with a market cap of A$1.89 billion.
Operations: The company generates revenue of $5.90 million from its cell technology platform development for commercialization.
Insider Ownership: 24.2%
Mesoblast is poised for growth, with revenue expected to rise 46% annually, surpassing market averages. The company is forecasted to achieve profitability within three years. Insider confidence is evident as substantial shares were bought recently, despite past shareholder dilution. Recent FDA designations for its therapy Revascor highlight potential in treating serious conditions, enhancing prospects. However, the company's Return on Equity is projected to remain low at 15.5% in three years.